Carr B.I.Rui F.Ince V.Yilmaz S.Zhao X.Feng Y.Li J.2024-08-042024-08-0420232770-5838https://doi.org/10.1002/poh2.60https://hdl.handle.net/11616/92104Aims: There are many studies on the incidence of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), but very little is known about the HCC features in different populations. The study aimed to compare characteristics in two cohorts of patients with HBV-associated hepatocellular carcinoma from Turkey and China. Methods: Data on patients with HBV-associated HCC diagnosed by imaging or liver biopsy were retrospectively collected from Shandong Provincial Hospital (n = 578) and Inonu University Hospital (n = 359) between January 2002 and December 2020, and the liver function and HCC characteristics were compared. Continuous variables were compared using Student's t-test or Mann–Whitney U test and categorical variables were compared using the ?² test or Fisher's exact test. Results: The patients in the Turkish cohort had significantly worse Child-Pugh scores (Child-Pugh A: 38.3% vs. 87.9%; Child-Pugh B: 40.3% vs. 11.1%; Child-Pugh C: 21.4% vs. 1.0%; p < 0.001) and significantly higher levels of aspartate aminotransferase (66.5 [38.0?126.0] vs. 36.0 [27.0?50.0] IU/L; p < 0.001), alanine aminotransferase (47.5 [30.0?87.3] vs. 33.0 [24.0?45.0] IU/L; p < 0.001), total bilirubin (20.8 [13.7?39.3] vs. 17.9 [13.8?24.0] mg/dL; p < 0.001), and lower albumin levels (32.0 [26.0?39.0] vs. 40.0 [36.1?43.8] g/L; p < 0.001) than patients in Chinese cohort. The tumor characteristics showed the Barcelona Clinic Liver Cancer (BCLC) score (BCLC 1: 5.1% vs. 71.8%; BCLC 2: 48.7% vs. 24.4%; BCLC 3: 24.4% vs. 3.8%; BCLC 4: 21.8% vs. 0; all p < 0.001), maximum tumor diameter (5.0 [3.0?9.0] vs. 3.5 [2.5?6.0] cm; p < 0.001), alpha-fetoprotein values (27.7 vs. 13.2 ng/mL; p < 0.001), and percentage of patients with portal vein tumor thrombus (33% vs. 6.1%; p < 0.001) were all significantly worse in the Turkish cohort compared with Chinese cohort. Conclusions: HBV-associated HCC from the Turkish cohort had worse liver function and more aggressive clinical characteristics than patients from the Chinese cohort. © 2023 The Authors. Portal Hypertension & Cirrhosis published by John Wiley & Sons Ltd on behalf of Chinese Medical Association.eninfo:eu-repo/semantics/closedAccessChinaHepatocellular CarcinomaTurkeyArticle10.1002/poh2.602-s2.0-85179949595N/A